<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04640636</url>
  </required_header>
  <id_info>
    <org_study_id>8070</org_study_id>
    <secondary_id>R01MH125155-01</secondary_id>
    <nct_id>NCT04640636</nct_id>
  </id_info>
  <brief_title>IM Ketamine vs Midazolam for Suicidal ER Patients</brief_title>
  <official_title>IM Ketamine vs Midazolam for Suicidal ER Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rising US suicide rates and the increased risk of suicide among persons who visit an&#xD;
      emergency department (ED) for suicidality make the ED an important site for interventions to&#xD;
      prevent suicide. There is no approved treatment for rapid relief of suicidal thoughts&#xD;
      although clinical trials, including ours, show relief of suicidal thoughts within hours of&#xD;
      treatment with inexpensive, generic, sub-anesthetic ketamine. We propose a clinical trial of&#xD;
      intramuscular ketamine in depressed ED patients with high-risk suicidality, which if&#xD;
      successful would support a novel, easy-to-use, scalable intervention for busy emergency&#xD;
      clinicians to implement.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rising US suicide rates and the increased risk of suicide among persons who visit an&#xD;
      emergency department (ED) for suicidality make the ED an important site for interventions to&#xD;
      prevent suicide. Clinical trials, including ours, show relief of suicidal thoughts within&#xD;
      hours of treatment with inexpensive, generic, subanesthetic ketamine. We have received NIMH&#xD;
      R01 funding to conduct a clinical trial of intramuscular (IM) ketamine in unipolar or bipolar&#xD;
      depressed adults who present to the CUIMC psychiatric ED with suicidality severe enough to&#xD;
      require inpatient hospitalization as judged by ED clinical staff. Clinical staff will ask&#xD;
      potentially eligible patients if they would like to learn more about the study, and if so, a&#xD;
      research assistant (RA) will describe the study to the patient and perform a basic&#xD;
      eligibility screen. Key exclusions are unstable medical problems, substance abuse, psychosis,&#xD;
      and further detail is provided in the Inclusion/Exclusion criteria. Participants (N=90) who&#xD;
      enroll will undergo baseline clinical ratings, brief cognitive testing, and then be&#xD;
      randomized, double-blind, in a 2:1 ratio to a single IM injection of ketamine (n=60) or&#xD;
      midazolam comparator (n=30). Vital signs and clinical state will be monitored until injection&#xD;
      effects subside (approximately 2 hrs). Blood samples will be drawn at 60 minutes and 90&#xD;
      minutes postinjection to assay ketamine level and a genetic sample will be stored. All&#xD;
      participants will then be admitted to the 9GN inpatient unit for standard clinical treatment&#xD;
      with periodic research follow-up ratings through 4 weeks post-discharge from hospital.&#xD;
      Ongoing outpatient treatment will be arranged by the inpatient clinical team. Positive&#xD;
      results from this trial would support a novel, easy-to-use, inexpensive, and scalable&#xD;
      intervention for busy emergency clinicians to implement.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2, 2021</start_date>
  <completion_date type="Anticipated">March 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Scale for Suicidal Ideation (SSI)</measure>
    <time_frame>24 hours post-treatment</time_frame>
    <description>Beck Scale for Suicidal Ideation clinician-rated version</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Systematic Assessment for Treatment Emergent Events (SAFTEE)</measure>
    <time_frame>24 hours post-treatment</time_frame>
    <description>Frequency of adverse events at 24 hours post-treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Depression, Unipolar</condition>
  <condition>Depression, Bipolar</condition>
  <condition>Suicidal Ideation</condition>
  <arm_group>
    <arm_group_label>Ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ketamine hydrochloride 0.5 mg/kg IM single injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>midazolam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Midazolam 0.06 mg/kg IM single injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine hydrochloride injection</intervention_name>
    <description>single IM injection of ketamine hydrochloride 0.5 mg/kg</description>
    <arm_group_label>Ketamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam injection</intervention_name>
    <description>single IM injection of midazolam 0.06 mg/kg</description>
    <arm_group_label>midazolam</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  DSM5 unipolar or bipolar (I, II, or Unspecified) major depressive episode&#xD;
&#xD;
          -  Presenting to emergency department and assessed by psychiatrist staff as needing&#xD;
             inpatient treatment due to suicidality&#xD;
&#xD;
          -  Participant agrees to voluntary inpatient psychiatric admission&#xD;
&#xD;
          -  Beck Scale for Suicidal Ideation score of 4 or higher&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Substance use disorder in past 2 weeks&#xD;
&#xD;
          -  Current psychosis or mania&#xD;
&#xD;
          -  Intellectual disability&#xD;
&#xD;
          -  Inadequate understanding of English and/or lack of capacity for informed consent&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Medical contraindication to ketamine or midazolam&#xD;
&#xD;
          -  Unstable medical or neurological illness such as uncontrolled hypertension,&#xD;
             significant cardiac arrhythmia, unstable cerebrovascular disease. Chronic, stable&#xD;
             medical conditions such as controlled hypertension or diabetes will not be excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Grunebaum, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York State Psychiatric Institute/Columbia University Irving Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Meghan Enslow, BA</last_name>
    <phone>646-774-7564</phone>
    <email>meghan.enslow@nyspi.columbia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael Grunebaum, MD</last_name>
    <phone>646-774-7573</phone>
    <email>michael.grunebaum@nyspi.columbia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Comprehensive Psychiatric Emergency Department of Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meghan Enslow, BA</last_name>
      <phone>646-774-7627</phone>
      <email>meghan.enslow@nyspi.columbia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Michael Grunebaum, MD</last_name>
      <phone>646-774-7573</phone>
      <email>michael.grunebaum@nyspi.columbia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Grunebaum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 20, 2020</study_first_submitted>
  <study_first_submitted_qc>November 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2020</study_first_posted>
  <last_update_submitted>February 18, 2021</last_update_submitted>
  <last_update_submitted_qc>February 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>New York State Psychiatric Institute</investigator_affiliation>
    <investigator_full_name>Michael Grunebaum, MD</investigator_full_name>
    <investigator_title>Research psychiatrist</investigator_title>
  </responsible_party>
  <keyword>depression</keyword>
  <keyword>suicidality</keyword>
  <keyword>clinical trial</keyword>
  <keyword>ketamine</keyword>
  <keyword>midazolam</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Suicidal Ideation</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All associated research findings published or provided to NIH, will be made readily available for research purposes to qualified individuals within the scientific community. All data will be made anonymous and available after written requests for data are submitted by such qualified individuals to the PI.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

